Somnomed Limited · ASX:SOM
Somnomed — H1 FY2014 Earnings Presentation
14 slides from Somnomed's earnings presentation, Feb 26, 2014
Slide 1: Investor Webinar Financial Year 2013-14 Half Year Review
For personal use only Investor Webinar Financial Year 2013 – 14 Half Year Review 26 February 2014 COAT ™ Continuous Open Airway Therapy
Slide 2: Disclaimer & Regulatory Disclosure
For personal use only Disclaimer & Regulatory Disclosure This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: SomnoMed Summary – First Half FY2014
SomnoMed: Global SomnoMed Summary – First Half FY2014 For personal use only 1 2 3 SomnoDent® Units sold totalled Revenues reached $12.5 million EBITDA $680k 20,455 Units Sold Revenues ($000's) EBITDA ($000's) 14,000 83% 800 25,000 135% 42% 12,000 20,000 10,000 15,000 8,000 400 6,000 10,000 4,000 5,0
Slide 4: Unit Sales Volume accelerates
SomnoMed: Global Unit Sales Volume accelerates For personal use only Quarterly Unit Growth % Unit sales by Region 12,000 11,000 29% 35% 10,000 11% 11% 9,000 8,000 60% 54% 7,000 6,000 2012 2013 5,000 North America APAC Europe Q1F12 Q2F12 Q3FY12 Q4FY12 Q1F13 Q2F13 Q3FY13 Q4FY13 Q1F14 Q2F14 4 COAT ™ Co
Slide 5: Acceleration of Revenue growth
SomnoMed: Global Acceleration of Revenue growth For personal use only Total Group Revenues ($000's) 14,000 12,000 CAGR = 41% 10,000 8,000 6,000 4,000 2,000 - HY 06/07 HY 07/08 HY 08/09 HY 09/10 HY 10/11 HY 11/12 HY 12/13 HY 13/14 5 COAT ™ Continuous Open Airway Therapy
Slide 6: Strong growth in Revenues and Gross Margin
SomnoMed: Global Strong growth in Revenues and Gross Margin For personal use only Half Year Revenue and Margin Growth ($000's) 14,000 12,000 CAGR Revenue = 41% Revenue growth HY13/14 over 10,000 CAGR Gross Margin = 50% HY12/13 was 39% 8,000 6,000 4,000 Consistent average Group Gross Margin of 65% 2,
Slide 7: Revenue Split balanced between US and Europe
SomnoMed: Global Revenue Split balanced between US and Europe For personal use only Total Revenues by Region 12% APAC North America 45% Europe 43% 7 COAT ™ Continuous Open Airway Therapy
Slide 8: Summary Profit and Loss
SomnoMed: Finance Summary Profit and Loss For personal use only Financial Summary ($000's) 13/14 12/13 11/12 1st H 1st H 1st H Units 20,455 17,182 14,443 Revenue 12,553 9,026 6,846 Gross Margin 8,129 5,962 4,515 Gross Margin % 65% 66% 66% Operating profit before corporate, business development and n
Slide 9: Growth in Underlying Profits funds investments to grow business
SomnoMed: Finance Growth in Underlying Profits funds investments to grow business For personal use only Financial Summary ($000's) 1st Half 1st Half 1st Half Underlying EBITDA FY12 FY13 FY14 SomnoMed continues to invest in its Revenues 6,846 9,026 12,553 future, with some sacrifice to the posted EBI
Slide 10: SomnoMed maintains solid cash position
SomnoMed: Finance SomnoMed maintains solid cash position For personal use only Quarterly Group Cash Balance 4,500,000 4,000,000 3,500,000 3,000,000 Cash Balance A$ 2,500,000 2,000,000 1,500,000 1,000,000 500,000 - FY12Q1 FY12Q2 FY12Q3 FY12Q4 FY13Q1 FY13Q2 FY13Q3 FY13Q4 FY14Q1 FY14Q2 Quarters by Fisc
Slide 11: North America: Good progress in improving the Dental Operation
SomnoMed: North America Good progress in improving the Dental Operation For personal use only > Service issues in Laboratory addressed with significant improvement in customer service > Successful launch of the SomnoDent® Herbst as a high quality and differentiated Medicare product > SomnoMed Prefer
Slide 12: North America: Indications of positive results of Medical Initiative
SomnoMed: North America Indications of positive results of Medical Initiative – Build up of Program to continue For personal use only • First test of medical concept positive > Initial interest and attendance at educational events good > Successful results from connecting SomnoMed dentists with slee
Slide 13: Outlook 2014 - The expansion continues
SomnoMed: Global Outlook 2014 - The expansion continues For personal use only 1. SomnoMed continues on the road of solid growth, expanding its core business and developing its future medical pathway: > Europe and APAC “Growth expected to continue”: • Growing demand due to insurer and physician suppo
Slide 14: Contact details
For personal use only Contact details EXECUTIVE CHAIRMAN AND CEO | Dr Peter Neustadt CHIEF FINANCIAL OFFICER | Mr Neil Verdal–Austin Address | Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone | +61 (2) 9467 0400 Website | www.somnomed.com.au COAT ™ Continuous Open Airway Therapy